Spanish and American researchers studied the clinical and serological data of patients with autoimmune myositis in relation to immune checkpoint inhibitor (ICI) treatment.
- Transcriptomic analysis were performed using RNA extracted from muscle biopsies,
- 35 biopsies from patients with ICI myositis were selected from 200 others,
- 3 transcriptomic profiles emerged (ICI-DM, ICI-MYO1 and ICI-MYO2), some of which had distinct clinical characteristics, particularly with regard to the presence of disturbances in the interferon pathway and/or the risk of myocarditis.
This study will help to better adjust the management and monitoring of this type of inflammatory myopathy of autoimmune origin.
